TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06126913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Antiretroviral Therapy
Description: Newly diagnosed individuals (diagnosed in the prior 6 months) at intervention sites will be offered community ART delivery on a rolling basis during the enrollment window, initiating individuals into groups as close to their date of diagnosis as possible. Newly enrolled individuals will join existing community ART delivery groups, or when a new group is needed based on group size or geographic location, a new group will be formed.
Study: NCT05770830

Intervention type: DEVICE
Intervention: Esophageal temperature
Description: Temperature data measured by esophageal temperature probe (disposable probe, Ace-medical, Seoul, Korea)

Intervention type: DEVICE
Intervention: Skin core temperature
Description: Temperature data measured by skin core temperature device measured by 3M™ Bair Hugger™
Study: NCT06290102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-56248
Description: Pharmaceutical form: Dry powder~Route of administration: Oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-56248
Description: Pharmaceutical form: Dry powder~Route of administration: Oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-56248
Description: Pharmaceutical form: Dry powder~Route of administration: Oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-56248
Description: Pharmaceutical form: Dry powder~Route of administration: Oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-56248
Description: Pharmaceutical form: Dry powder~Route of administration: Oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TEV-56248
Description: Pharmaceutical form: Dry powder~Route of administration: Oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fp MDPI
Description: Pharmaceutical form: Dry powder~Route of administration: Oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fp MDPI
Description: Pharmaceutical form: Dry powder~Route of administration: Oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fp MDPI
Description: Pharmaceutical form: Dry powder~Route of administration: Oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fp MDPI
Description: Pharmaceutical form: Dry powder~Route of administration: Oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fp MDPI
Description: Pharmaceutical form: Dry powder~Route of administration: Oral inhalation
Study: NCT05567211

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personalized nutritional planning with an extra intake of berries + physical exercise + use of mobile application.
Description: Access to the virtual platform + nutritional planning with an extra supply of antioxidants using red berries + physical activity. The platform will allow the registration of all the evolution, monitoring of nutritional and sports patterns (with activity bracelet), as well as oxidative stress, hydration, menstrual phase and mood.
Study: NCT06290102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fp MDPI
Description: Pharmaceutical form: Dry powder~Route of administration: Oral inhalation
Study: NCT05106933

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Plain water
Description: Measure gastric residual volume during upper endoscopic, after given plain water and carborie 2 hours prior upper endoscopy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carborie
Description: carbohydrate drink
Study: NCT05004428

Intervention type: OTHER
Intervention: No intervention
Description: Retrospective population-based study utilizing administrative data without any intervention.
Study: NCT05123599

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 injection will be administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-64300535
Description: JNJ-64300535 deoxyribonucleic acid (DNA) vaccine injection will be administered intramuscularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETV monohydrate
Description: ETV monohydrate film-coated tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil
Description: Tenofovir disoproxil film-coated tablets will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAF
Description: TAF film-coated tablets will be administered orally.
Study: NCT06518161

Intervention type: OTHER
Group type: OTHER
Intervention: Voluntary
Description: Subjects undergoing scheduled surgery in the operating room at Nantes University Hospital, requiring general anesthesia with placement of an endotracheal intubation tube for invasive mechanical ventilation.
Study: NCT06501443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Treatment after acute event approved in the country where patient is based. It may include educational intervention according to each country guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Treatment after acute event approved in the country where patient is based. It may include educational intervention according to each country guidelines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KJX839
Description: Inclisiran in solution for subcutaneous injection on day 1, day 90, and day 270
Study: NCT05099172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088_formulation A
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088_formulation A
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088_formulation B_1
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088_formulation B_1
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088_formulation B_1
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088_formulation B_1
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088_formulation B_2
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088_formulation B_2
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088_formulation B_2
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2927088_formulation B_2
Description: Oral administration
Study: NCT05300971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat therapy
Description: 36 sessions (\~3x per week for 12 weeks) of hot water immersion in 40°C water, sufficient to raise body core temperature to 38.5°C, and 12 weeks of follow-up.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Thermoneutral water immersion
Description: 36 sessions (\~3x per week for 12 weeks) of thermoneutral water immersion in 36°C water to prevent changes in body core temperature \>0.2°C, and 12 weeks of follow-up.
Study: NCT05127304

Intervention type: DEVICE
Intervention: Trelegy Ellipta
Description: Trelegy Ellipta with Furoate/Umeclidinium/Vilanterol

Intervention type: DEVICE
Intervention: Stiolto Respimat
Description: Stiolto Respimat with Tiotropium Bromide/Olodaterol

Intervention type: DRUG
Intervention: Furoate/Umeclidinium/Vilanterol
Description: Furoate/Umeclidinium/Vilanterol

Intervention type: DRUG
Intervention: Tiotropium Bromide/Olodaterol
Description: Tiotropium Bromide/Olodaterol
Study: NCT04988906

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zoll Accuvent Ventilation Monitor
Description: Provides real-time ventilation quality monitoring (rate and volume)
Study: NCT06392113

Intervention type: BEHAVIORAL
Intervention: ACTION FALLS
Description: Falls prevention advice including booklet and videos
Study: NCT06103409

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Implantation of allogeneic MSCs on burn wounds
Description: Transplantation of allogeneic MSCs in patients with deep- or full-thickness burns. Allogeneic MSCs embedded in autologous platelet rich plasma clot (PRP) are implanted onto the burned areas. The treated areas will be covered with conventional dressings and burned roll. Dressings will be changed after 5 days and then weekly. The total number of MSCs used in each patient varied according to the burn injury. In patients with larger burned areas, its necessary to apply new treatments with MSCs in affected areas, at intervals of at least 1 month. Implantation will be performed in the operating room. Patients will receive first line treatments.
Study: NCT06392113

Intervention type: BEHAVIORAL
Intervention: ACTION FALLS
Description: Falls prevention advice including booklet and videos

Intervention type: BEHAVIORAL
Intervention: ACTION FALLS
Description: Falls prevention advice including booklet and videos
Study: NCT06440408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Description: Ferumoxytol will be used as a contrast agent for the cMRI
Study: NCT00429923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT06205628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-850
Description: siRNA duplex oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-850
Description: siRNA duplex oligonucleotide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADX-850
Description: siRNA duplex oligonucleotide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin Receptor Blockers
Description: Angiotensin receptor blocker
Study: NCT05126901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Maltol
Description: Ferric maltol oral suspension: 150 ml amber glass bottle with graduated syringe and adaptor. Oral suspension containing 30 mg elemental iron, in the form of 231.5 mg ferric maltol, in 5 ml suspension~Study dosage: The dose of ferric maltol oral suspension that will be administered for children aged 1 month to \< 2 yrs: 0.1 ml/kg BID, 2 to - 11 yrs: 2.5 ml BID, 12-17 yrs: 5 ml BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Maltol
Description: Ferric maltol oral suspension: 150 ml amber glass bottle with graduated syringe and adaptor. Oral suspension containing 30 mg elemental iron, in the form of 231.5 mg ferric maltol, in 5 ml suspension~Study dosage: The dose of ferric maltol oral suspension that will be administered for children aged 1 month to \< 2 yrs: 0.1 ml/kg BID, 2 to - 11 yrs: 2.5 ml BID, 12-17 yrs: 5 ml BID.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferrous sulfate
Description: Ferrous sulfate 125 mg/ml (25 mg/ml elemental iron) oral liquid : 15 ml glass bottle.~Study dosage: For ferrous sulfate oral liquid, the dose administered will be for children and adolescents aged 2 years to 17 yrs: 6 mg/kg to the maximum of 4 ml BID.
Study: NCT04286282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Pyschotherapy
Description: Group psychotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Depression Standard of Care
Description: Standard clinical care for depression, which may include the use of selective serotonin re-uptake inhibitors (SSRIs).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Depression Standard of Care
Description: Standard clinical care for depression, which may include the use of selective serotonin re-uptake inhibitors (SSRIs).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIV Standard of Care
Description: Standard clinical care for HIV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HIV Standard of Care
Description: Standard clinical care for HIV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV Standard of Care
Description: Standard clinical care for HIV
Study: NCT05572736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conduction system pacing
Description: Pacing from the His-Purkinje system (His-bundle pacing, left bundle branch area pacing, or deep septal pacing).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biventricular pacing
Description: Pacing from the coronary sinus and right ventricular leads.
Study: NCT05201963

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus Anterior Plane Block
Description: Full aseptic precautions applied. Ultrasound probe will be placed on the patient's midaxillary line in the longitudinal plane (lateral position with arm abduction), at the level of 5th rib, the indicator oriented toward the operator's left. With the rib, pleural line, overlying serratus anterior and latissimus dorsi muscles visualized, then, a 38-mm 22-gauge regional block needle will be advanced in-plane at an angle of approximately 45 degrees towards the 5th rib. After aspiration to avoid intravascular injection 30ml of levobupivacaine 0.25% will be injected anteriorly to the rib and deep to the serratus anterior muscle. The entirety of the needle should be visualized at all times throughout the procedure.6-13-MHz, linear transducer set for small parts and a depth of 1-4 cm is used for this block(15-16).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: Full aseptic precautions applied. Ultrasound probe will be placed on the back in a transverse orientation to identify the tip of the T5 transverse process. The tip of the transverse process will be centered on the ultrasound screen and the probe will then be rotated into a longitudinal orientation to produce a parasagittal view, in which skin, subcutaneous tissue, trapezius and erector spinae muscle will be visible superficial to T5 transverse process. Echogenic block needle will be inserted in- plane to the ultrasound beam in a cranial-to-caudal direction until contact is made with the T5 transverse process. Correct location of the needle tip in the fascial plane deep to erector spinae muscle will be confirmed by injecting 0.5-1 ml normal saline . After aspiration to avoid intravascular injection 30 ml levobupivacaine 0.25% will be performed. 6-13-MHz, linear transducer set for small parts and a depth of 4-6 cm will be used
Study: NCT06236607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device specific training
Description: Device-specific training materials from the manufactures will be used. The study clinician/pump trainer will use a pump readiness check-list to evaluate the training needs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device specific training
Description: Device-specific training materials from the manufactures will be used. The study clinician/pump trainer will use a pump readiness check-list to evaluate the training needs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device specific training
Description: Device-specific training materials from the manufactures will be used. The study clinician/pump trainer will use a pump readiness check-list to evaluate the training needs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study clinician/educator visit
Description: Participants will receive insulin dose and other diabetes management guidance.
Study: NCT05400265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX26
Description: Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX26
Description: Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX26
Description: Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: Humanized Anti-Programmed Death-1 Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: Humanized Anti-Programmed Death-1 Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: Humanized Anti-Programmed Death-1 Monoclonal Antibody
Study: NCT04906577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: photography+odour
Description: Daily from D0 to D5: a square of cotton cloth will be placed against the child's scalp by the childcare worker in charge of the child, then removed and placed in a sealed box containing a photograph of the child, which will then be given to the mother.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: photography
Description: A neutral smelling cloth will be placed with the child's photograph which will then be given to the mother.
Study: NCT05421663

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-90014496
Description: JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) - T cell therapy targeting Cluster of differentiation (CD)19 and CD20.
Study: NCT06572748

Intervention type: OTHER
Group type: OTHER
Intervention: 10-week programme
Description: 1. 2-week health education (4 sessions, 60 minutes per session) Social workers and occupational therapists will explain the cognitive training elements of the program and introduce the DementiAbility Methods to the participants. Nutritionist, speech therapists, and Chinese medicine practitioner will share insights from their perspectives to enhance participants' understanding of cognitive impairments.~2. 8-week cooking class (5 sessions, 120 minutes per session) The culinary instructor will teach participants to cook homemade dishes while integrating procedural memory into recipes. Older adults and their caregivers will cook together based on the procedural recipe designed by caregivers, aiming to enhance communication between them and create joyful memories. The cooking class will begin with 20-30 minutes an interactive nutrition-based session. The session themes will focus on healthy diet and food safety. Participants will be able to ask questions and make comments.

Intervention type: OTHER
Group type: OTHER
Intervention: 10-week programme
Description: 1. 2-week health education (4 sessions, 60 minutes per session) Social workers and occupational therapists will explain the cognitive training elements of the program and introduce the DementiAbility Methods to the participants. Nutritionist, speech therapists, and Chinese medicine practitioner will share insights from their perspectives to enhance participants' understanding of cognitive impairments.~2. 8-week cooking class (5 sessions, 120 minutes per session) The culinary instructor will teach participants to cook homemade dishes while integrating procedural memory into recipes. Older adults and their caregivers will cook together based on the procedural recipe designed by caregivers, aiming to enhance communication between them and create joyful memories. The cooking class will begin with 20-30 minutes an interactive nutrition-based session. The session themes will focus on healthy diet and food safety. Participants will be able to ask questions and make comments.
Study: NCT05332275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Arm - T.E.C.H. Parenting
Description: Intervention Arm participants will enroll in a web-based psychoeducational group (15 parents per group across 4 groups). Participants will receive psychoeducational information on media parenting, and they will be invited to participate in an online group discussion board to share their experiences with other parents in the intervention. In weeks 2-5, participants will learn about 4 domains of media parenting: 1) Talk to your child about media; 2) Educate your child about media-related risks; 3) Co-View/Co-Use media and technology actively with your child; and 4) establish House rules for media usage. Week 6 will review information and provide an expert clinician to support parent problem solving. Participants will receive 2-3 weekly push messages via text messaging prompting practice of skills learned in the group setting. Participants will be assessed at baseline, immediately following the 6 week intervention, and 3 months after the intervention is completed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm - General Positive Parenting
Description: The Control Arm of the RCT is the attention control group. These participants will enroll in a web-based psychoeducational group (four groups of 15 parents each). They will receive 6 weeks of online psychoeducational material, including 2-3 push messages prompting skill practice. Parents will have access to an online discussion board to share experiences with other parents. This group will match the intervention arm of the study in number of study staff contacts, time of start/duration of the group, peer support, and availability of a professional in week six for consultation on parenting issues. Control participants will not receive information on media parenting. Participants in this group will be assessed at baseline, immediately following the six-week intervention period, and 3 months after intervention completion. Participants will be asked about exposure to TECH Parenting content at baseline and followup to address potential contamination effects across study arms.
Study: NCT05141435

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: infants receive primary non-invasive respiratory support by mean of nCPAP
Description: neonates assigned to the nCPAP group will be started on a pressure of 6 cmH2O( adjust range:6-10 cmH2O) , with FiO2 (0.21-0.40)adjusted to target SpO2 from 89% to 94%. CPAP will be provided by either variable flow or continuous flow devices, as there is no clear evidence that one type of CPAP generator would be better than any other by pure CPAP system.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: infants receive primary non-invasive respiratory support by mean of nCPAP
Description: neonates assigned to the nCPAP group will be started on a pressure of 6 cmH2O( adjust range:6-10 cmH2O) , with FiO2 (0.21-0.40)adjusted to target SpO2 from 89% to 94%. CPAP will be provided by either variable flow or continuous flow devices, as there is no clear evidence that one type of CPAP generator would be better than any other by pure CPAP system.
Study: NCT05575401

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral pharyngoplasty
Description: Two figure-of-8 sutures using 3-0 vicryl are used to approximate the anterior and posterior tonsillar pillars and reconstruct the continuous mucosal covering of the lateral pharyngeal walls.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tonsillectomy
Description: Extracapsular tonsillectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Description: Extracapsular tonsillectomy